Targeting Interleukin-17 As a Novel Treatment Option for Fibrotic Diseases

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Jan 11

PMID 38202170

Authors

Margherita Sisto

Sabrina Lisi

Affiliations

Soon will be listed here.

Abstract

Fibrosis is the end result of persistent inflammatory responses induced by a variety of stimuli, including chronic infections, autoimmune reactions, and tissue injury. Fibrotic diseases affect all vital organs and are characterized by a high rate of morbidity and mortality in the developed world. Until recently, there were no approved antifibrotic therapies. In recent years, high levels of interleukin-17 (IL-17) have been associated with chronic inflammatory diseases with fibrotic complications that culminate in organ failure. In this review, we provide an update on the role of IL-17 in fibrotic diseases, with particular attention to the most recent lines of research in the therapeutic field represented by the epigenetic mechanisms that control IL-17 levels in fibrosis. A better knowledge of the IL-17 signaling pathway implications in fibrosis could design new strategies for therapeutic benefits.

Citing Articles

"The Ameliorative Effect of Interleukin-17A Neutralization on Doxorubicin-Induced Cardiotoxicity by Modulating the NF-κB/NLRP3/Caspase-1/IL-1β Signaling Pathway in Rats".

Hassen M, Mousa N, Radwan S, Gabre R Inflammation. 2025; .

PMID: 40064794 DOI: 10.1007/s10753-024-02187-z.

Novel Factors Regulating Proliferation, Migration, and Differentiation of Fibroblasts, Keratinocytes, and Vascular Smooth Muscle Cells during Wound Healing.

Smith J, Rai V Biomedicines. 2024; 12(9).

PMID: 39335453 PMC: 11429312. DOI: 10.3390/biomedicines12091939.

IL-17 is associated with disease severity and targetable inflammatory processes in heart failure.

Baumhove L, van Essen B, Dokter M, Zijlstra S, Deiman F, Laman J ESC Heart Fail. 2024; 11(6):3530-3538.

PMID: 39031992 PMC: 11631355. DOI: 10.1002/ehf2.14968.

References

Wang B . Base Composition Characteristics of Mammalian miRNAs. J Nucleic Acids. 2013; 2013:951570. PMC: 3595719. DOI: 10.1155/2013/951570. View

Chen S, Zhang X, Yang C, Wang S, Shen H . Essential role of IL-17 in acute exacerbation of pulmonary fibrosis induced by non-typeable . Theranostics. 2022; 12(11):5125-5137. PMC: 9274745. DOI: 10.7150/thno.74809. View

Raphael I, Joern R, Forsthuber T . Memory CD4 T Cells in Immunity and Autoimmune Diseases. Cells. 2020; 9(3). PMC: 7140455. DOI: 10.3390/cells9030531. View

Owyang A, Zaph C, Wilson E, Guild K, Mcclanahan T, Miller H . Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med. 2006; 203(4):843-9. PMC: 1800834. DOI: 10.1084/jem.20051496. View

Wick G, Grundtman C, Mayerl C, Wimpissinger T, Feichtinger J, Zelger B . The immunology of fibrosis. Annu Rev Immunol. 2013; 31:107-35. DOI: 10.1146/annurev-immunol-032712-095937. View

Liu Y, Wen D, Ho C, Yu L, Zheng D, OReilly S . Epigenetics as a versatile regulator of fibrosis. J Transl Med. 2023; 21(1):164. PMC: 9983257. DOI: 10.1186/s12967-023-04018-5. View

OReilly S, Hugle T, van Laar J . T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012; 51(9):1540-9. DOI: 10.1093/rheumatology/kes090. View

Hu X, Zou Y, Copland D, Schewitz-Bowers L, Li Y, Lait P . Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2. EBioMedicine. 2022; 86:104333. PMC: 9646865. DOI: 10.1016/j.ebiom.2022.104333. View

Castro-Villegas C, Perez-Sanchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limon P . Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther. 2015; 17:49. PMC: 4377058. DOI: 10.1186/s13075-015-0555-z. View

10.

Huang X, Zhang H, He M . Comparative and Evolutionary Analysis of the Interleukin 17 Gene Family in Invertebrates. PLoS One. 2015; 10(7):e0132802. PMC: 4517768. DOI: 10.1371/journal.pone.0132802. View

11.

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

12.

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

13.

Wu W, Tsai Y, Lin T, Wu M, Lin C . The attenuation of renal fibrosis by histone deacetylase inhibitors is associated with the plasticity of FOXP3IL-17 T cells. BMC Nephrol. 2017; 18(1):225. PMC: 5504832. DOI: 10.1186/s12882-017-0630-6. View

14.

Zhang Y, Chen X, Deng Y . miR-125a-3p decreases levels of interlukin-17 and suppresses renal fibrosis via down-regulating TGF-β1 in systemic lupus erythematosus mediated Lupus nephritic mice. Am J Transl Res. 2019; 11(3):1843-1853. PMC: 6456516. View

15.

Gaffen S, Jain R, Garg A, Cua D . The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14(9):585-600. PMC: 4281037. DOI: 10.1038/nri3707. View

16.

Starnes T, Broxmeyer H, Robertson M, Hromas R . Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol. 2002; 169(2):642-6. DOI: 10.4049/jimmunol.169.2.642. View

17.

Pastor W, Aravind L, Rao A . TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013; 14(6):341-56. PMC: 3804139. DOI: 10.1038/nrm3589. View

18.

Monin L, Gaffen S . Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. Cold Spring Harb Perspect Biol. 2017; 10(4). PMC: 5732092. DOI: 10.1101/cshperspect.a028522. View

19.

Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T . The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. Mediators Inflamm. 2017; 2017:3908061. PMC: 5337858. DOI: 10.1155/2017/3908061. View

20.

Ritzmann F, Lunding L, Bals R, Wegmann M, Beisswenger C . IL-17 Cytokines and Chronic Lung Diseases. Cells. 2022; 11(14). PMC: 9318387. DOI: 10.3390/cells11142132. View